Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
Completed
National Cancer Institute (NCI)
Phase 1
2001-07-01
Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some
block the ability of cancer cells to grow and spread. Others find cancer cells and help kill
them or deliver cancer-killing substances to them. Drugs used in chemotherapy work in
different ways to stop tumor cells from dividing so they stop growing or die. Radiation
therapy uses high-energy x-rays to damage tumor cells. Combining monoclonal antibody therapy
with chemotherapy and radiation therapy may be an effective treatment for head and neck
cancer. This phase I trial is to see if combining bevacizumab, fluorouracil, and hydroxyurea
with radiation therapy works in treating patients who have advanced head and neck cancer
It is desirable to obtain extended follow up data on subjects who participated in the 2NN
study and the CHARM study in order to see if the beneficial effect of using nevirapine
continues up to 144 weeks of treatment.
It is desirable to obtain extended follow up data on subjects who participated in the 2NN
study and the CHARM study in order to see if the beneficial effect of using nevirapine
continues up to 144 weeks of treatment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.